Trade name
of Fosfogliv®
the International unlicensed name
Is not present
the Dosage form
of the Structure One Capsule Capsule contains
active agents - phospholipids (lipoid C80) (in terms of 100% substance) 65.0 mg (the main component phosphatidylsincaline of 73-79%), acids of glitsirrizinovy trinatriyevy salt (sodium glycyrrhizinate) 35.0 mg,
excipients: microcrystalline cellulose, calcium carbonate, calcium stearate, talc, silicon dioxide colloidal (aerosil).
Structure of a cover of the capsule:
Capsules firm gelatinous No. 0
body: titan dioxide (E 171), ferrous oxide red (E 172), methylparahydroxybenzoate (methylhydroxybenzoate), propilparagidroksi-benzoate (propilgidroksibenzoat), acetic acid, gelatin.
lid: titan dioxide (E 171), ferrous oxide black (E 172), methylparahydroxybenzoate (methylhydroxybenzoate), propilparagidroksi-benzoate (propilgidroksibenzoat), acetic acid, gelatin
or
Capsules firm gelatinous No. 0
body: titan dioxide (E 171), ferrous oxide red (E 172), gelatin.
lid: titan dioxide (E 171), ferrous oxide black (E 172), gelatin.
The description
of the Capsule firm gelatinous No. 0, the capsule body – orange color, a lid – black color. Capsule contents – the granulated powder from white with slightly yellowish shade till light yellow color, with a slight specific smell.
Pharmacotherapeutic group
Drugs for treatment of diseases of a liver
the Code of automatic telephone exchange A05BA
the Pharmacological
Pharmacokinetics Components properties of drug are well soaked up in intestines, as in the form of the whole molecules, and bioactive hydrolysates (unsaturated fatty acids, sincaline, glitsirretovy acid) which after absorption through intestines walls easily get into a liver, lungs, skin and other bodies.
A pharmacodynamics
the Combined means. Has membrane stabilizing, hepatoprotective and antiviral effect.
Fosfatidilkholin (active ingredient of phospholipids) is the basic structural element of cellular and intracellular membranes, is capable to restore their structure and functions at damage, having cytoprotective effect. Normalizes proteinaceous and lipidic exchanges, prevents loss by hepatocytes of enzymes and other active agents, restores detoksitsiruyushchy function of a liver, inhibits forming of connective tissue, reducing risk of developing of fibrosis and cirrhosis.
Glitsirat (glycyrrhizic acid and salts) possesses anti-inflammatory action, suppresses a reproduction of viruses in a liver and other bodies due to stimulation of products of interferon, increase in phagocytosis, increase in activity of natural cells killers. Has hepatoprotective effect thanks to antioxidant and membranstabiliziruyushchy activity. Exponentiates action of endogenous glucocorticosteroids, having anti-inflammatory and antiallergic effect at non-infectious damages of a liver.
At damages of skin due to membrane stabilizing and anti-inflammatory action of components limits distribution of process and promotes regress of a disease.
Indications
- a viral hepatitis (sharp and chronic)
- fatty degeneration of a liver (hepatosis)
- other damages of a liver (medicinal, alcoholic, toxic)
- cirrhosis
- intoxications
- psoriasis
- neurodermatitis
- eczema
Accept the Route of administration and doses inside, at meal time, washing down with a small amount of liquid. To adults and children 12 years on 1-2 capsules 3-4 times a day are more senior.
Duration of a course of therapy is defined by the doctor. Duration of a course can be increased according to the recommendation of the doctor.
Side effects
- at the increased individual sensitivity the appearance of skin rash which disappears after drug withdrawal is possible.
- when exceeding daily doses the delay of sodium and liquid, hypostases
- increase in arterial blood pressure
- a hypopotassemia can be noted
At emergence of the specified symptoms, depending on their expressiveness, it is necessary to reduce a dose of drug and/or to appoint Spironolactonum of 50-100 mg a day.
Contraindications
- hypersensitivity to drug components
- pregnancy and in the period of a lactation
- children's age up to 12 years
Medicinal interactions
are not described.
Special instructions
At patients with portal hypertensia.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms.
Data on negative influence of drug on ability to drive the car or to work with mechanisms are absent.
Overdose
of Cases of overdose of drug it was not noted.
Glycyrrhizic acid which is a part of drug in high doses can cause the pseudo-corticosteroid effect representing increase in level of glucocorticosteroids and mineralokortikoid in blood. It leads to a delay of sodium and reduction of potassium in an organism and, as a result, to increase in level of arterial blood pressure, a water delay in an organism.
Treatment: in case of overdose symptomatic treatment
the Form of release and packing
On 10 capsules in blister strip packaging from a film of the polyvinylchloride and printing aluminum foil varnished.
5 blister strip packagings together with the instruction for medical use in the state and Russian languages place in a pack from cardboard.
Storage conditions
At a temperature not higher than 20 ºС.
To store out of children's reach!
3 years
not to use a period of storage after the expiration date specified on packing!
Prescription status
According to the prescription
the Producer
of joint stock company Pharmstandard-Leksredstva
of Fosfogliv®
the International unlicensed name
Is not present
the Dosage form
of the Structure One Capsule Capsule contains
active agents - phospholipids (lipoid C80) (in terms of 100% substance) 65.0 mg (the main component phosphatidylsincaline of 73-79%), acids of glitsirrizinovy trinatriyevy salt (sodium glycyrrhizinate) 35.0 mg,
excipients: microcrystalline cellulose, calcium carbonate, calcium stearate, talc, silicon dioxide colloidal (aerosil).
Structure of a cover of the capsule:
Capsules firm gelatinous No. 0
body: titan dioxide (E 171), ferrous oxide red (E 172), methylparahydroxybenzoate (methylhydroxybenzoate), propilparagidroksi-benzoate (propilgidroksibenzoat), acetic acid, gelatin.
lid: titan dioxide (E 171), ferrous oxide black (E 172), methylparahydroxybenzoate (methylhydroxybenzoate), propilparagidroksi-benzoate (propilgidroksibenzoat), acetic acid, gelatin
or
Capsules firm gelatinous No. 0
body: titan dioxide (E 171), ferrous oxide red (E 172), gelatin.
lid: titan dioxide (E 171), ferrous oxide black (E 172), gelatin.
The description
of the Capsule firm gelatinous No. 0, the capsule body – orange color, a lid – black color. Capsule contents – the granulated powder from white with slightly yellowish shade till light yellow color, with a slight specific smell.
Pharmacotherapeutic group
Drugs for treatment of diseases of a liver
the Code of automatic telephone exchange A05BA
the Pharmacological
Pharmacokinetics Components properties of drug are well soaked up in intestines, as in the form of the whole molecules, and bioactive hydrolysates (unsaturated fatty acids, sincaline, glitsirretovy acid) which after absorption through intestines walls easily get into a liver, lungs, skin and other bodies.
A pharmacodynamics
the Combined means. Has membrane stabilizing, hepatoprotective and antiviral effect.
Fosfatidilkholin (active ingredient of phospholipids) is the basic structural element of cellular and intracellular membranes, is capable to restore their structure and functions at damage, having cytoprotective effect. Normalizes proteinaceous and lipidic exchanges, prevents loss by hepatocytes of enzymes and other active agents, restores detoksitsiruyushchy function of a liver, inhibits forming of connective tissue, reducing risk of developing of fibrosis and cirrhosis.
Glitsirat (glycyrrhizic acid and salts) possesses anti-inflammatory action, suppresses a reproduction of viruses in a liver and other bodies due to stimulation of products of interferon, increase in phagocytosis, increase in activity of natural cells killers. Has hepatoprotective effect thanks to antioxidant and membranstabiliziruyushchy activity. Exponentiates action of endogenous glucocorticosteroids, having anti-inflammatory and antiallergic effect at non-infectious damages of a liver.
At damages of skin due to membrane stabilizing and anti-inflammatory action of components limits distribution of process and promotes regress of a disease.
Indications
- a viral hepatitis (sharp and chronic)
- fatty degeneration of a liver (hepatosis)
- other damages of a liver (medicinal, alcoholic, toxic)
- cirrhosis
- intoxications
- psoriasis
- neurodermatitis
- eczema
Accept the Route of administration and doses inside, at meal time, washing down with a small amount of liquid. To adults and children 12 years on 1-2 capsules 3-4 times a day are more senior.
Duration of a course of therapy is defined by the doctor. Duration of a course can be increased according to the recommendation of the doctor.
Side effects
- at the increased individual sensitivity the appearance of skin rash which disappears after drug withdrawal is possible.
- when exceeding daily doses the delay of sodium and liquid, hypostases
- increase in arterial blood pressure
- a hypopotassemia can be noted
At emergence of the specified symptoms, depending on their expressiveness, it is necessary to reduce a dose of drug and/or to appoint Spironolactonum of 50-100 mg a day.
Contraindications
- hypersensitivity to drug components
- pregnancy and in the period of a lactation
- children's age up to 12 years
Medicinal interactions
are not described.
Special instructions
At patients with portal hypertensia.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms.
Data on negative influence of drug on ability to drive the car or to work with mechanisms are absent.
Overdose
of Cases of overdose of drug it was not noted.
Glycyrrhizic acid which is a part of drug in high doses can cause the pseudo-corticosteroid effect representing increase in level of glucocorticosteroids and mineralokortikoid in blood. It leads to a delay of sodium and reduction of potassium in an organism and, as a result, to increase in level of arterial blood pressure, a water delay in an organism.
Treatment: in case of overdose symptomatic treatment
the Form of release and packing
On 10 capsules in blister strip packaging from a film of the polyvinylchloride and printing aluminum foil varnished.
5 blister strip packagings together with the instruction for medical use in the state and Russian languages place in a pack from cardboard.
Storage conditions
At a temperature not higher than 20 ºС.
To store out of children's reach!
3 years
not to use a period of storage after the expiration date specified on packing!
Prescription status
According to the prescription
the Producer
of joint stock company Pharmstandard-Leksredstva
Related Products
Sigma Pharmaceutical Industries for the World Medical, UK (Egypt
Choludexan (Ursodeoxycholic Acid) 300 mg, 20 capsules
$40.10
